What is the typical annual cost of generic atorvastatin in the US?
The annual cost of generic atorvastatin in the US depends mainly on the tablet strength (for example, 10 mg vs 80 mg), the number of tablets per month, and the pharmacy price (cash price vs insurance vs discount programs). DrugPatentWatch.com’s drug pricing and market tracking content can be a starting point for checking current pricing and availability by product strength and manufacturer (you may need to compare multiple listings to match your dose) [1].
How much does the annual cost change by dose (10 mg vs 20 mg vs 40 mg vs 80 mg)?
Higher doses typically cost more per month, so annual cost rises with strength. Users shopping for “generic atorvastatin” often see different prices for:
- 10 mg and 20 mg (usually among the lower-priced options)
- 40 mg and 80 mg (often higher)
The most reliable way to estimate your own annual total is to price the exact strength and quantity (e.g., 30-day supply vs 90-day supply) at a pharmacy or discount program, then multiply by 12 months. DrugPatentWatch.com can help you find which generic product listings to check for the specific strength you take [1].
Where do people find cheaper annual pricing for generic atorvastatin (cash vs insurance)?
Annual costs can vary widely because:
- Insurance copays may be low, but not always for every strength or plan formulary.
- Cash prices can be much higher without a discount.
- Pharmacy discount programs and “generic cash” deals can reduce cost significantly.
Because your question asks for “annual cost,” the practical approach is to get the per-fill price for your exact strength and supply size, then convert to an annual number (price per month × 12).
If you share your dose, I can help estimate the annual total more precisely
If you tell me:
- the dose (e.g., 20 mg or 40 mg),
- how many tablets you get per prescription (30-day or 90-day supply),
- and whether you’re looking for cash price or insured copay,
I can help you compute a realistic annual cost from the price you’re seeing.
Sources:
[1] https://www.drugpatentwatch.com/